Research News

Parkinson's Reseach at university of Queensland

Alpha-synuclein Research Progress for Parkinson’s

Saturday, 1 July 2017

As researchers search for a therapy to slow or stop Parkinson’s disease (PD) progression, alpha-synuclein has emerged as a leading target. This protein clumps in the brains of nearly everyone with Parkinson’s and it’s the primary component of Lewy bodies,…

Study to Understand Exercise Preferences in Parkinson’s disease

Wednesday, 28 June 2017

The University of Sydney invites you to take part in a research study about the exercise preferences of people with Parkinson’s disease. Summary There is increasing evidence supporting the benefits of exercise for people with Parkinson’s disease (PD). Exercise improves motor…


Could Parkinson’s disease be an autoimmune disorder?

Monday, 26 June 2017

Could Parkinson’s disease be an autoimmune disorder? A recent study from Columbia University revealed a possible link between the immune system — the body’s defense system against disease — and alpha-synuclein, the sticky protein that clumps in the cells of…

Gut Check on Parkinson’s: New Findings on Bacteria Levels

Tracing the Origins of Parkinson’s to the Gut

Thursday, 4 May 2017

There is a lot of clinical and research data to suggest the gut is involved in Parkinson’s disease (PD). Constipation, a prominent non-motor symptom associated with PD, occurs years prior to diagnosis in many people. Alpha-synuclein, the sticky protein that…

Parkinson's Research

New Data on Extended-Release Amantadine for Dyskinesia

Monday, 1 May 2017

Over the past year or so, we’ve told you about a dyskinesia drug that is advancing toward U.S. Food and Drug Administration (FDA) approval. This week, Adamas Pharmaceuticals announced new data for this therapy, an extended-release formulation of amantadine designed…

Blood test may confirm parkinsons diagnosis

Making Strides Toward Parkinson’s Biomarker

Monday, 24 April 2017

At the current time, there is no identified biomarker for Parkinson’s disease (PD). In other words, there is no objective measure — no lab or imaging test, for example — that can tell whether a person has PD, what type…

Todd Sherer

MJFF CEO on Parkinson’s Disease 200th: “Hope Remains”

Monday, 17 April 2017

In recognition of Parkinson’s Awareness month, MJFF CEO Todd Sherer, PhD, penned an op-ed for Scientific American about the current state of Parkinson’s disease (PD) research, 200 years after Dr. James Parkinson formally characterised the disease. In the commentary, Dr….

New Research Confirms Role of LRRK2 in Immune Cells

Monday, 10 April 2017

Though associated with only a small percentage of total Parkinson’s cases, mutations of the LRRK2 gene are the greatest known genetic contributor to Parkinson’s disease (PD). Researchers are striving to understand the mechanisms of disease related to this mutation because…